Development of carbapenem resistance during therapy for non-typhoid Salmonella infection  by Su, L.H. et al.
Development of carbapenem resistance
during therapy for non-typhoid Salmonella
infection
L. H. Su1,2,3, T. L. Wu1,2,3 and C. H. Chiu2,3,4
1) Department of Laboratory Medicine, 2) Molecular Infectious Disease
Research Centre, Chang Gung Memorial Hospital, Linkou, 3) Chang
Gung University College of Medicine, Taoyuan and 4) Department of
Paediatrics, Chang Gung Memorial Hospital, Linkou, Taiwan
Abstract
Multidrug-resistant Salmonella infection is a global problem, and
carbapenems may represent the last therapeutic choice. We
report a case of infection caused by ceftriaxone-resistant and
ciprofloxacin-resistant Salmonella enterica serotype Typhimurium.
A blaCMY-2-containing Tn6092, located on a self-transferable
IncI1 plasmid, was found in all isolates derived from the patient.
During ertapenem treatment, the strain developed carbapenem
resistance. Apart from the OmpD deficiency found in all isolates,
the strain further developed OmpC deficiency through a single
gene mutation, and became carbapenem-resistant. Salmonella
appears to be very plastic in developing antimicrobial resistance.
Care must be taken by physicians when treating multidrug-resis-
tant Salmonella infection.
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Non-typhoid Salmonella causes self-limited foodborne infec-
tions as well as invasive infections that require antimicrobial
therapy [1]. Appropriate therapeutic agents may include
ampicillin, trimethoprim–sulphamethoxazole, chlorampheni-
col, fluoroquinolones, or expanded-spectrum cephalosporins
[2]. However, rates of resistance of Salmonella clinical iso-
lates to the traditional antibiotics are high, and in recent
years only fluoroquinolones and expanded-spectrum cephalo-
sporins have remained effective against non-typhoid Salmo-
nella infection [2]. Unfortunately, resistance to these agents
has also increased in Salmonella [2]. For patients with inva-
sive, multidrug-resistant Salmonella infection, carbapenems
may represent the last resort [3]. The emergence of carba-
penem resistance in Salmonella therefore represents a seri-
ous clinical problem, owing to the lack of other therapeutic
choices.
In 2010, a clinical isolate of carbapenem-resistant Salmo-
nella enterica serotype Typhimurium was identified in a 3500-
bed university hospital in Taiwan. The study was undertaken
to investigate the associated carbapenem resistance mecha-
nisms. Antimicrobial susceptibility of the isolates was exam-
ined by a standard disk diffusion method, and MICs were
assessed with Etest strips (AB Biodisk, Solna, Sweden). The
results were categorized according to the suggestions of the
CLSI [4]. The genetic relatedness of the isolates was investi-
gated by pulsed-field gel electrophoresis [5]. Genes for ceph-
alosporinases (SHVs, TEMs, CTX-Ms, and AmpCs) and
carbapenemases (IMPs, KPCs, VIMs, and OXAs) were ampli-
fied by PCR and sequenced [6–8]. Plasmid analysis and
DNA–DNA hybridization were used to locate the resistance
genes [6]. Conjugation, replicon typing and plasmid multilo-
cus sequence typing were used to characterize the resistance
plasmids [9,10]. The expression of the two major outer
membrane proteins, OmpC and OmpD, of Salmonella Ty-
phimurium was analysed by RT-PCR with the following pri-
mer pairs designed according to the published sequence
(GenBank accession no. FQ312003): RT-OmpC-F, 5¢-GGC
GCTATCACCACGTCTAAAC-3¢; RT-OmpC-R, 5¢-TTGG
CAAAACCGTAAGAGG-3¢; RT-OmpD-F, 5¢-GCGCAGT
ACCAGGGCAAAAACGAC-3¢; and RT-OmpD-R, 5¢-CAGA
CCAGCAGCCCAGACTTCAGC-3¢. DNA sequences of the
two outer membrane proteins were also analysed by PCR
and sequencing with the following primer pairs (GenBank
accession no. FQ312003): OmpC-F (5¢-ATCCGGTTGAAA
TAGGGGTAA-3¢) and OmpC-R (5¢-GGTGGACATGTTT
TTGTTGAAGTA-3¢); and OmpD-F (5¢-GTGCTCCYCCTGC
GCCATACCA-3¢) and OmpD-R (5¢-TCCGCAAAGACAAC
GACCAGTGAA-3¢).
A 77-year-old woman with nephritic syndrome and
chronic renal insufficiency was hospitalized several times for
medical treatment. On 14 February, she had an onset of
urinary tract infection, and was hospitalized again through
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the emergency department. Salmonella Typhimurium (U1)
was identified in the urine culture. The strain was resistant
to ampicillin, chloramphenicol, trimethoprim–sulphamethox-
azole, and ceftriaxone, but remained susceptible to carba-
penems (ertapenem, 0.064 mg/L; imipenem, 0.25 mg/L) and
tigecycline. Ciprofloxacin was reported as resistant, with a
resistant zone diameter (14 mm) of nalidixic acid according
to the CLSI’s suggestions [4]. The patient was given ertape-
nem (1 g once-daily), but developed diarrhoea during the
therapy. Stool culture yielded Salmonella Typhimurium (S1)
of the same antibiogram. Follow-up cultures of both urine
and stool specimens invariably grew Salmonella Typhimurium
(U2/S2 and U3/S3), also of the same antibiogram. The
patient was discharged after the symptoms and signs of uri-
nary tract infection resolved. In April, the patient was hos-
pitalized again, owing to a right leg crush injury. The initial
wound culture yielded ceftriaxone-resistant Proteus mirabilis,
and ertapenem was prescribed on 19 April. She received
wound debridement on 21 April. The wound pus yielded
Salmonella Typhimurium (W1) of the same antibiogram as
those described above (Table 1). The patient subsequently
had persistent diarrhoea, and the stool culture again grew
Salmonella Typhimurium (S4). The antibiogram of strain S4
was similar to those of the other Salmonella Typhimurium
isolates derived from this patient, except that strain S4 was
resistant to carbapenems (ertapenem, >32 mg/L; imipenem,
8 mg/L) (Table 1). The patient was put under contact isola-
tion, and was kept on ertapenem therapy. She was dis-
charged without serious sequelae after appropriate wound
debridement.
A total of eight isolates, three from urine, four from stool,
and one from wound cultures, of Salmonella Typhimurium
were recovered from the patient. Except for strain U2, the
remaining seven isolates were available for further molecular
investigation (Table 1). Identical pulsed-field gel electropho-
resis patterns were found among the isolates, indicating that
the isolates were of the same lineage. A blaCMY-2 gene was
present in all isolates, and was the only ceftriaxone resis-
tance gene identified. The blaCMY-2 gene was located in a
Tn6092 that has previously been identified in S. enterica
serotype Choleraesuis SC-B67 and several members of the
Enterobacteriaceae [6,11]. The Tn6092 was carried on a 115-
kb IncI1 plasmid of the ST54 plasmid multilocus sequence
type. The IncI1 plasmid was demonstrated to be self-trans-
ferable. MICs of ceftriaxone increased from 0.064 to 64 mg/
L, whereas those of carbapenems (ertapenem, 0.064 mg/L;
imipenem, 0.25 mg/L) remained low, in the recipient strain
Escherichia coli J53 after receiving the blaCMY-2-containing
IncI1 plasmid.
None of the known carbapenemase genes was identified
from the carbapenem-resistant strain, S4. The low MIC
(1 mg/L) of tigecycline suggested that efflux pumps were not
TABLE 1. Laboratory finding among the Salmonella Typhimurium isolates studied
Bacteria
Specimen
Plasmid profilea (kb)
RNA expressionb
OmpCd, amino acid 77Date Type OmpDc OmpCd
U1 14 February Urine (115, 210) 0.0006 1.09 W (TGG)
S1 19 February Stool (115) 0.0008 0.88 W (TGG)
S2 2 March Stool (115, 210) 0.0007 0.98 W (TGG)
S3 9 March Stool (115, 210) 0.0008 1.14 W (TGG)
U3 9 March Urine (115, 210) 0.0011 0.61 W (TGG)
W1 21 April Wound (115, 210) 0.0004 0.97 W (TGG)
S4 27 April Stool (115, 210) 0.0056 0.04 Stop (TGA)
aThe blaCMY-2-harbouring IncI1 plasmid is underlined.
bRNA expression level is given as the fold of expression relative to that of 16S rRNA in each strain as revealed by RT-PCR.
cAs compared with that of Salmonella Typhimurium LBNP4417, the expression level of OmpD was low among the isolates, presumably because of an IS1 insertion between
ompD and its promoter region (Fig. 1).
dAs compared with that of other isolates tested, the expression level of OmpC was low in the carbapenem-resistant strain, S4, probably because of the amino acid change
from tryptophan (W, TGG) to a stop codon (TGA) at codon 77.
FIG. 1. Schematic presentation of ompD (Salmonella Typhimurium
SL1344, FQ312003) genetic structure, showing the insertion of IS1
in the carbapenem-resistant Salmonella Typhimurium (S4) isolate.
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involved in the carbapenem resistance. OmpD deficiency was
found in all isolates, probably because of the insertion of IS1
88 bp upstream of ompD (Fig. 1). In the carbapenem-resis-
tant strain, S4, OmpC deficiency was also evident, as shown
by the low expression level revealed by RT-PCR (Table 1). A
point mutation was identified at codon 77 of ompC, leading
to an amino acid change from tryptophan (TGG) to a stop
codon (TGA), and thus the early termination of the protein
(Table 1).
Carbapenem resistance resulting from the production of
extended-spectrum b-lactamases (ESBLs) or AmpCs plus po-
rin deficiency is frequently reported in E. coli and Klebsiella
pneumoniae [7,8], but very rarely in Salmonella. There has
been only one report demonstrating, in an imipenem-resis-
tant strain of S. enterica serotype Wien, that the imipenem
resistance was related to CMY-4 b-lactamase production and
porin loss [12]. In the present study, OmpD, an analogue of
OmpK35 in K. pneumoniae or OmpF in E. coli, was deficient
in every isolate. This is common for isolates that produce
ESBLs or AmpCs [7,8]. After the use of ertapenem, the
expression of OmpC, an analogue of OmpK36 in K. pneumo-
niae or OmpC in E. coli, was further reduced, leading to the
carbapenem resistance phenotype.
Carbapenem resistance can also occur through the pro-
duction of carbapenem-hydrolysing enzymes [13]. Although
the mechanism is frequently reported in E. coli and K. pneu-
moniae [13], the presence of such enzymes, including IMP-4,
IMP-13, and KPC-2, has been only sporadically reported in
Salmonella [14–16]. Carbapenem resistance resulting from
the production of carbapenemases in Enterobacteriaceae is
infrequent in Taiwan [7,8]; in contrast, another mechanism
associated with the production of ESBLs or AmpCs and
porin deficiency appears more commonly.
We previously identified, in several serotypes of non-
typhoid Salmonella, a self-transferable blaCMY-2-harbouring
IncI1 plasmid that has contributed to the overall increase of
ceftriaxone resistance in Salmonella [10]. In the case reported
herein, the ceftriaxone resistance of all Salmonella Typhimuri-
um isolates was also attributable to the presence of such
self-transferable IncI1 plasmids. The porin change occurred
8 days after the use of ertapenem during the second hospi-
talization of the patient, and resulted in a more than 32-fold
increase in the carbapenem MICs.
Increasing ceftriaxone resistance caused by the spread of
ESBL or AmpC genes in non-typhoid Salmonella has been
reported worldwide [10,17–19]. Our study has demon-
strated that resistance of these ceftriaxone-resistant Salmo-
nella isolates to carbapenems may emerge during ertapenem
therapy. Salmonella appears to be very adaptive to antimicro-
bial selection pressure [20]. Physicians should be aware of
this possibility, and all patients under therapy for non-typhoid
Salmonella infection should be carefully monitored.
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